Pharmesis International Ltd. provided earnings guidance for the six months ended June 30, 2022. For the period, the company expected net loss was mainly due to the control measures such as lockdowns taken by China to contain the spread of the COVID-19 pandemic, which has resulted in a decrease in sales.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.08 SGD | -38.93% | 0.00% | -18.37% |
Apr. 15 | Pharmesis’ Attributable Loss for 2023 Widens | MT |
Apr. 15 | Pharmesis International Ltd. Announces the Retirement of Ms. Lin Yimin as a Director | CI |
1st Jan change | Capi. | |
---|---|---|
-18.37% | 1.62M | |
+25.61% | 672B | |
+25.87% | 570B | |
-5.24% | 360B | |
+16.49% | 321B | |
+8.28% | 300B | |
+7.09% | 217B | |
-9.12% | 204B | |
+5.01% | 199B | |
-8.75% | 149B |
- Stock Market
- Equities
- BFK Stock
- News Pharmesis International Ltd.
- Pharmesis International Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2022